Recently the IABS “Conclusion and Recommendation” of the Munich conference about “Autogenous Vaccines: quality of production and movement in a common market” have been published at the IABS congress website.
The “Conclusion and Recommendation” is available at IABS website
Challenged by a format of a hybrid meeting at Munich University LMU the response of the participants was extraordinary positive: 86% of all participants have been very or highly satisfied with the conference at all. This remarkable level of satisfaction was reported for the scientific content of the meeting, the quality of the lectures and discussions as well as for the COVID-19 owed hybrid format of the meeting. And best reflection of the audience: 96% of all participants are highly interested in a follow-up meeting about Autogenous vaccines!
In total 146 experts from countries all over Europe, from Asia and the US participated at the conference about “Autogenous Vaccines: Quality of Production and Movement in a Common Market” on 14th to 16th of September, whereof 59 participated on site in Munich.
The EMAV Proposal: “EU-GMP-Annex for Autogenous vaccines”, developed by the association of European Manufacturers of Autogenous Vaccines and Sera (EMAV), was integral part of the scientific dialogue of the conference. The results of this scientific excursus will be incorporated in the IABS – EMAV meeting report to be published in the scientific journal “Biologicals”.
The EMAV position paper is available at EMAV website - Position Paper